Hyderabad’s Apollo Hospitals successfully undertakes a rare tendon augmentation procedure, as reported by Telangana Today.
A groundbreaking surgical procedure was successfully performed by Dr. Prashant Meshram, a renowned shoulder surgeon, at Apollo Hospitals in Jubilee Hills, Hyderabad. The 58-year-old patient had been suffering from chronic pain and significant weakness in his right shoulder for over six months following a fall. The patient’s condition had significantly impacted his daily life, and conventional treatments had provided little relief.
Dr. Meshram and his team decided to perform an innovative procedure called lower trapezius transfer, which involved the use of an allograft tendon (Achilles tendon) augmentation. This complex surgery aimed to restore the patient’s shoulder mechanics, alleviate pain, and prevent the progression of arthritis. The procedure was performed arthroscopically, allowing for minimal invasion and faster recovery.
The surgical team carefully executed the transfer, rerouting the biceps tendon and repairing the subscapularis tendon. This comprehensive approach ensured that the patient’s shoulder joint alignment and function were restored. Post-operative imaging confirmed the success of the procedure, showing a reversal of superior head migration, a critical indicator of restored joint alignment and function.
The successful outcome of this procedure is a testament to Dr. Meshram’s expertise and the exceptional care provided by the surgical team at Apollo Hospitals. The use of allograft tendon augmentation in lower trapezius transfer is a relatively new and innovative approach, and this case demonstrates its potential in treating complex shoulder injuries. With this procedure, the patient is expected to experience significant improvement in his shoulder function and a reduction in pain, allowing him to resume his daily activities without restriction. The success of this surgery is a positive development for patients suffering from similar conditions, offering new hope for effective treatment and improved quality of life.
Aurobindo Pharma subsidiary receives US FDA approval for generic version of Bristol Myers Squibb’s cancer treatment
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Dasatinib Tablets in various strengths. The approved product is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company’s (BMS) Sprycel Tablets. Dasatinib Tablets are used to treat certain types of leukemia, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.
The approval is significant, as the estimated market size for the product is $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT numbers. The company plans to launch the product by June. This is the 181st Abbreviated New Drug Application (ANDA) approval received by Eugia Pharma Specialities Group (EPSG) facilities, which manufacture both oncology oral and sterile specialty products.
Dasatinib Tablets are indicated for the treatment of newly diagnosed adults with Ph+ chronic myeloid leukemia in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy. The product is also used to treat adults with Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
The approval demonstrates Aurobindo Pharma’s commitment to expanding its product portfolio and increasing its presence in the global pharmaceutical market. The company’s subsidiary, Eugia Pharma Specialities, has a strong track record of receiving FDA approvals, with 181 ANDA approvals to date. The launch of Dasatinib Tablets is expected to contribute to the company’s revenue growth and help it achieve its business objectives.
Overall, the FDA approval of Dasatinib Tablets is a significant milestone for Aurobindo Pharma and its subsidiary, Eugia Pharma Specialities. The product has the potential to make a significant impact in the treatment of certain types of leukemia, and the company is well-positioned to capitalize on the growing demand for affordable and effective pharmaceuticals.
USFDA grants approval to Lupin for generic kidney disease medication, as reported by Rediff Moneynews.
Lupin Ltd, a leading pharmaceutical company, has received approval from the US Food and Drug Administration (USFDA) for its generic version of Tolvaptan tablets. The tablets are indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a certain type of kidney disease. The approval is for Tolvaptan tablets in strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, which are bioequivalent to Jynarque tablets manufactured by Otsuka Pharmaceutical Company Ltd.
Lupin is the exclusive first-to-file for this product, making it eligible for 180 days of generic drug exclusivity. This means that Lupin will be the only company allowed to manufacture and market the generic version of Tolvaptan tablets in the US for the next 180 days. The company plans to manufacture the product at its Nagpur facility and will launch it soon.
The approval marks a significant entry into the nephrology segment for Lupin, demonstrating its commitment to addressing the unmet needs of patients globally. Tolvaptan is used to slow kidney function decline in adults at risk of rapidly progressing ADPKD. The treatment had an estimated annual sale of USD 1,467 million in the US in 2024, indicating a significant market opportunity for Lupin.
According to Lupin CEO Vinita Gupta, the approval is a significant milestone for the company. “This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally,” she said. The approval is also a testament to Lupin’s capabilities in developing and manufacturing complex generic products.
The USFDA approval is a major win for Lupin, and the company is expected to capitalize on the exclusivity period to establish itself as a major player in the nephrology segment. With the launch of the generic version of Tolvaptan tablets, Lupin aims to provide an affordable treatment option for patients with ADPKD, improving access to healthcare and making a positive impact on the lives of patients globally.
IPL 2025: Kavya Kalanithi Maran Reveals The Secret Behind Her Radiant Complexion On Camera – myKhel
The Indian Premier League (IPL) 2025 is underway, and the excitement is palpable. While the cricketing action on the field is exhilarating, the cameras also can’t help but focus on the stylish and glamorous personalities attending the matches. One such personality is Kavya Kalanithi Maran, the daughter of Sun TV Network’s owner Kalanithi Maran. She has been making headlines with her stunning appearances at the IPL matches, and her flawless skin has caught everyone’s attention.
Kavya’s skin looks radiant and glowing, even in the harsh camera lights. So, what’s her secret to achieving such flawless skin? According to sources, Kavya’s skincare routine is a combination of traditional and modern methods. She believes in taking care of her skin from the inside out, which means she focuses on a healthy diet, adequate hydration, and regular exercise. She also swears by the importance of getting enough sleep, which helps to rejuvenate her skin and keep it looking fresh.
In addition to her lifestyle habits, Kavya is also particular about her skincare products. She prefers to use natural and organic products that are gentle on her skin and free from harsh chemicals. She has been known to use a range of skincare products, including face masks, serums, and moisturizers, that are rich in antioxidants and other nourishing ingredients. Kavya is also a fan of traditional Indian skincare remedies, such as using turmeric and gram flour to exfoliate and brighten her skin.
Kavya’s makeup artist has also revealed that she prefers a natural and effortless makeup look. She avoids heavy makeup and instead opts for a light, dewy finish that enhances her natural features. Her makeup routine typically includes a lightweight foundation, a swipe of mascara, and a bold lip color. Kavya’s hair is also always styled to perfection, with a sleek blowout or a chic updo that complements her outfit.
Overall, Kavya Kalanithi Maran’s secret to flawless skin is a combination of healthy lifestyle habits, a consistent skincare routine, and a light-handed approach to makeup. She is an inspiration to many young women who aspire to achieve healthy and glowing skin. As the IPL 2025 continues, we can’t wait to see more of Kavya’s stunning appearances and get a glimpse into her beauty secrets. With her impeccable style and flawless skin, she is sure to turn heads and make a statement at every match.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.